dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Navarro Mendivil, Alejandro |
dc.contributor.author | Callejo Perez, Ana |
dc.contributor.author | Iranzo Gómez, Patricia |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Martínez Marti, Alexandre |
dc.contributor.author | Pardo Aranda, Nuria |
dc.contributor.author | Jiménez Flores, José Antonio |
dc.contributor.author | Sansano Valero, Irene |
dc.contributor.author | Mancuso, Francesco Mattia |
dc.contributor.author | Nuciforo, Paolo Giovanni |
dc.contributor.author | Vivancos Prellezo, Ana |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Amat, Ramon |
dc.contributor.author | Saoudi Gonzalez, Nadia |
dc.contributor.author | Carbonell, Caterina |
dc.contributor.author | Frigola Rissech, Joan |
dc.date.accessioned | 2021-12-01T13:17:30Z |
dc.date.available | 2021-12-01T13:17:30Z |
dc.date.issued | 2021-04 |
dc.identifier.citation | Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, et al. Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887–900. |
dc.identifier.issn | 1574-7891 |
dc.identifier.uri | https://hdl.handle.net/11351/6634 |
dc.description | Carga de alteraciones cromosómicas; Inhibidores de los puntos de control inmunitarios; Carga mutacional del tumor |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Molecular Oncology;15(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject | Pulmons - Càncer - Prognosi |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | Progression-Free Survival |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /therapeutic use |
dc.title | Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/1878-0261.12891 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | supervivencia libre de progresión |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1002/1878-0261.12891 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Frigola J, Carbonell C, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Navarro A, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Jimenez J, Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sansano I] Unitat de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mancuso FM, Vivancos A] Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33342055 |
dc.identifier.wos | 000605076800001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00938 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |